We scan new podcasts and send you the top 5 insights daily.
Microcystic keratopathy from belantamab mafodotin involves superficial corneal epithelial changes rather than posterior chamber damage. Lengthening treatment intervals to every 8 to 12 weeks and delaying doses allows vision to recover while maintaining deep, MRD-negative therapeutic responses.
For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.
Clinicians mitigate Belantamab's ocular toxicity by extending dosing intervals to every 8-12 weeks. This is effective due to the drug's long half-life and often allows vision to recover between doses, sometimes even deepening responses without sacrificing disease control.
Due to significant ocular toxicity affecting most patients, the approved starting dose for belantumab is likely not optimal long-term. Effective management requires clinicians to proactively hold, delay, and reduce doses at the first sign of side effects, meaning real-world application will differ from the initial protocol.
Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.
Clinicians are successfully managing Belantamab's primary side effect, keratopathy, by using lower starting doses and extending dosing intervals to every 8 or 12 weeks once a response is seen. This maintains efficacy while significantly improving tolerability for patients.
When managing ocular toxicity from the ADC mirvetuximab, clinicians advocate for delaying the subsequent dose to allow the cornea to heal naturally. This approach is often preferred over an immediate dose reduction, which might unnecessarily compromise the treatment's efficacy.
A major logistical barrier to using belantamab is the required ophthalmic monitoring. However, these exams don't require a specialist ophthalmologist. Routine tests can be performed by a community optometrist, making the drug more accessible for patients and providers outside of large academic centers and lowering adoption barriers.
The KVA grading scale for Bellemaf's ocular side effects can trigger a grade 2 event based on an ophthalmologist's exam, even if the patient's functional vision (e.g., ability to read or drive) is unaffected. This disconnect between clinical grading and patient experience is crucial for managing treatment holds and counseling.
For the ADC belantamab mafodotin, clinicians should not feel rigidly bound to the initial every-three-week schedule. Data shows that spreading doses out to every 8 or 12 weeks is a viable strategy, as most patients stabilize or even improve their depth of response despite holding the drug, allowing for better toxicity management.
The DREAM 9 trial suggests that standard every-3-week dosing of belantamab is too frequent. Extending the interval to every 6, 8, or 12 weeks maintained high efficacy while significantly improving patients' vision-related functioning and quality of life, pointing towards a new, more tolerable standard of care.